title: [Epidermic growth factor receptor (EGFR) in glioblastomas: the mechanism of tumorigenesis and its role as a therapeutic target].
abstract: A glioblastoma is a primary brain tumour that is very aggressive and resistant to conventional treatment with chemo- or radiotherapy. Given that epidermic growth factor receptor (EGFR) is altered in 50% of glioblastomas, it is currently one of the most promising therapeutic targets in this kind of tumour. Yet, inhibitors of the kinase activity of EGFR have yielded poor results in clinical trials with patients with glioblastomas. In this review we analyse the function of EGFR in glioblastomas and outline the therapeutic approaches aimed against this receptor in this kind of tumour. This sort of analysis could be a starting point for improving the design of future therapies for glioblastomas, based on inhibiting the EGFR function.
authors.affiliation: Instituto de Salud Carlos III , Majadahonda, Espana.
authors.forename: Cristina
authors.initials: C
authors.lastname: Zahonero
authors.forename: Juan M
authors.initials: JM
authors.lastname: Sepúlveda
authors.forename: Pilar
authors.initials: P
authors.lastname: Sánchez-Gómez
mesh_terms: D001932:Brain Neoplasms / Q000188:drug therapy* / Q000209:etiology*; D063646:Carcinogenesis; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000502:physiology*; D005909:Glioblastoma / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans
chemical_list: C512478:EGFR protein, human; D066246:ErbB Receptors